Jim Cramer on Pfizer Inc. (PFE) CEO Albert Bourla: ‘President-elect Trump Felt That Bourla Was A Hero During COVID’
We recently published an article titled Jim Cramer Discussed These 21 Stocks As Bond Yields Soared. In this article, we are ...
STAT7h
A biotech legend, pharma CEO, and two Trump admin vets walk into JPM Day 2
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.
Pfizer Eyes $20 Billion Revenue From Acquisitions Amid Patent Cliff Challenges
While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I ...
Pfizer CEO Bourla says Starboard Value wants minimal changes, Bloomberg says
CEO Albert Bourla said the company’s dispute with activist firm Starboard Value isn’t “an aggressive situation,” months after the ...
Biopharma industry eyes 2025 bounceback, grapples with uncertainty over Trump return
The biopharmaceutical industry is aiming for a 2025 reversal of last year's slump in investor returns but remains wary over ...
FiercePharma17h
JPM25: BMS, Pfizer and Merck CEOs address key patent cliffs and plans to replace sales
Monday, three Big Pharma leaders took center stage and addressed concerns about future patent expirations head-on.
BioSpace17h
Pfizer Cautiously Optimistic on Obesity Pill as Kailera Challenges Lilly’s Zepbound With Strong Phase II Data
Obesity continues to grab attention at the J.P. Morgan Healthcare Conference in San Francisco, with both Pfizer and Kailera ...
Pfizer CEO Is Optimistic Ahead of the Trump Administration. ‘The Opportunities Outweigh the Risks.’
Pfizer CEO Albert Bourla said he had spoken to Robert F. Kennedy Jr. in an effort to “find opportunities on things we can ...
FiercePharma1d
JPM25, Day 1: Pfizer CEO discusses plan to overcome $17B 'LOE wave'
Welcome to day 1 of the J.P. Morgan Healthcare Conference, the industry's most significant dealmaking event each year.  | For ...
BioSpace14h
JPM25 Day One: Pfizer, BioNTech, Moderna and More Present Pipeline Updates
Biopharma executives were busy Monday, striking high-value deals and providing updates on cancer, obesity and vaccine pipelines.